Evofem initiated with an Outperform at RBC Capital. RBC Capital analyst Randall Stanicky initiated Evofem with an Outperform rating and a price target of $8, saying the company offers exposure to a “large, evolving Women’s market that has lacked innovation”. The analyst sees its lead product – Amphora – “filling a void” as a non-hormonal on-demand contraceptive, and cites the findings of his survey of over 1K women to support his peak sales estimates of $357M by 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.